Comparative Pharmacology
Head-to-head clinical analysis: DIFICID versus SEPTRA DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFICID versus SEPTRA DS.
DIFICID vs SEPTRA DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
SEPTRA DS is a combination of trimethoprim and sulfamethoxazole. Trimethoprim inhibits bacterial dihydrofolate reductase, while sulfamethoxazole inhibits dihydropteroate synthase, sequentially blocking folate synthesis and ultimately DNA synthesis in susceptible bacteria.
200 mg (tablet) orally twice daily for 10 days.
One DS tablet (800 mg sulfamethoxazole/160 mg trimethoprim) orally every 12 hours for 10-14 days.
None Documented
None Documented
11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing.
Trimethoprim: 8-10 hours; sulfamethoxazole: 10-12 hours (prolonged in renal impairment, e.g., creatinine clearance <30 mL/min increases half-life to >20 hours).
Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor).
Renal excretion of unchanged drugs accounts for 50-70% of trimethoprim and 20-30% of sulfamethoxazole; biliary excretion is minor (<10% total).
Category C
Category C
Antibiotic
Antibiotic